SEHK:1244Biotechs
3D Medicines (SEHK:1244) Loss Narrows To C¥0.36 EPS And Tests Bearish Narratives
3D Medicines (SEHK:1244) has released its FY 2025 first half figures, reporting revenue of C¥209.2 million and a basic EPS loss of C¥0.36 per share, underscoring that the business is still in loss-making territory. Over recent periods, the company has seen revenue range from C¥206.4 million in 1H 2024 to C¥239.2 million in 2H 2024, while basic EPS moved between losses of C¥0.42 and C¥0.32 per share. This gives investors a clearer view of how revenue scale and per share losses have tracked...